Semantic Scholar Open Access 2019

Selective Janus kinase inhibitors: Promising drugs for rheumatoid arthritis

A. Zanwar A. Aggarwal

Lihat Sumber DOI

Abstrak

Burmester GR, Kremer JM, Bosch FV den, Kivitz A, Bessette L, Li Y, Zhou Y, Othman AA, Pangan AL, Camp HS. (Charité– Universitätsmedizin, Berlin, Germany; Albany Medical College, Albany, NY, USA; VIB-UGent Center for Inflammation Research, Department of Internal Medicine, Ghent University, and Department of Rheumatology, Ghent University Hospital, Ghent, Belgium; Altoona Center for Clinical Research, Duncansville, PA, USA; Laval University, Quebec, QC, Canada; and AbbVie Inc, North Chicago, IL, USA.) Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs (SELECT-NEXT): A randomised, double-blind, placebocontrolled phase 3 trial. Lancet 2018;391:2503–12

Topik & Kata Kunci

Medicine

Penulis (2)

A. Zanwar

A. Aggarwal

Format Sitasi

APA MLA BibTeX

Zanwar, A., Aggarwal, A. (2019). Selective Janus kinase inhibitors: Promising drugs for rheumatoid arthritis. https://doi.org/10.4103/0970-258X.275350

Akses Cepat

Lihat di Sumber doi.org/10.4103/0970-258X.275350

Informasi Jurnal

Tahun Terbit: 2019
Bahasa: en
Sumber Database: Semantic Scholar
DOI: 10.4103/0970-258X.275350
Akses: Open Access ✓